Peptide Sequence Modifications: Amidation, Acetylation and Lipidation
The short answer
A peptide’s amino-acid sequence is only part of its identity. N-terminal acetylation, C-terminal amidation and lipidation change the molecular structure and can alter charge, mass, enzyme susceptibility, solubility, binding, aggregation and distribution.
A modified peptide and its unmodified sequence should be treated as different materials unless evidence establishes their relationship for the question being studied.
C-terminal amidation
Replacing a terminal carboxyl group with an amide neutralizes one negative charge and changes molecular mass. Many endogenous peptide hormones are naturally amidated, and amidation can be required for receptor activity or can influence resistance to carboxypeptidases.
The effect is sequence-dependent. Amidation does not universally increase potency or stability, and it must be confirmed analytically rather than inferred from a name.
N-terminal acetylation
Acetylation caps the N-terminal amino group, changing charge and molecular mass. It may affect recognition by aminopeptidases, conformation or biological interaction. An acetylated fragment is not analytically identical to the free-amine fragment even when the amino-acid letters are otherwise the same.
Lipidation
Lipidation covalently attaches a fatty-acid or other lipid moiety, often through a linker and a selected residue. In pharmaceutical design, lipidation may increase protein binding, alter self-association, slow clearance or change tissue exposure.
Those properties depend on lipid chain, attachment site, linker, sequence and formulation. Evidence for one lipidated analogue cannot be transferred to another or to the unmodified parent peptide.
Modification changes analytical expectations
Each modification changes expected molecular mass and may alter chromatographic retention, ionization, solubility and impurity patterns. Identity testing should use the exact specified structure. A mass result matching an unmodified sequence would not confirm an amidated, acetylated or lipidated target.
Modification is not the same as formulation
A covalent sequence modification changes the molecule. A counter-ion, salt, buffer or excipient is associated with the material but is not ordinarily part of the peptide’s covalent sequence. Both can affect experiments, but they belong in different parts of the specification.
Key points
- Terminal modifications change peptide chemistry.
- Amidation and acetylation alter terminal charge and mass.
- Lipidation adds a larger hydrophobic group and can change distribution and persistence.
- Effects are sequence- and context-dependent.
- Modified and unmodified materials require distinct identity evidence.
What this article does not establish
This article does not establish that a modification makes a peptide safer, more effective or suitable for human use. It does not certify the modification state or identity of any AURAPEP material.
References
- Merkler DJ. C-terminal amidated peptides: production by the in vitro enzymatic amidation of glycine-extended peptides. Enzyme Microb Technol. 1994. https://pubmed.ncbi.nlm.nih.gov/7764886/
- Polevoda B, Sherman F. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation. J Mol Biol. 2003. https://pubmed.ncbi.nlm.nih.gov/12527337/
- Zhang L, Bulaj G. Converting peptides into drug leads by lipidation. Curr Med Chem. 2012. https://pubmed.ncbi.nlm.nih.gov/22376031/
- Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018. https://pubmed.ncbi.nlm.nih.gov/28720325/